48 related articles for article (PubMed ID: 32243362)
1. Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy.
Okada S; Yamazaki S; Kaiga T; Funada T; Kochi M; Takayama T
World J Surg Oncol; 2017 Aug; 15(1):162. PubMed ID: 28836976
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of natural killer cells injection combined with XELOX chemotherapy in postoperative patients with stage III colorectal cancer in China: a prospective randomised controlled clinical trial study protocol.
Geng S; Yu X; Yu S
BMJ Open; 2024 Mar; 14(3):e080377. PubMed ID: 38531576
[TBL] [Abstract][Full Text] [Related]
3. Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen.
He WZ; Rong YM; Jiang C; Liao FX; Yin CX; Guo GF; Qiu HJ; Zhang B; Xia LP
Chin J Cancer; 2016 Jun; 35(1):58. PubMed ID: 27357402
[TBL] [Abstract][Full Text] [Related]
4. Value of combined detection of serum carcino-embryonic antigen, carbohydrate antigen 19-9 and cyclooxygenase-2 in the diagnosis of colorectal cancer.
Yang W; Luo Y; Hu S; Li Y; Liu Q
Oncol Lett; 2018 Aug; 16(2):1551-1556. PubMed ID: 30008836
[TBL] [Abstract][Full Text] [Related]
5. Expression and clinical significance of CA125, CA153 and CEA in nipple discharge of breast cancer patients.
Geng J; Jinli S; Guo W; Li H; Dan Y; Gao Y
J Med Biochem; 2024 Apr; 43(2):234-242. PubMed ID: 38699697
[TBL] [Abstract][Full Text] [Related]
6. Prediction models of colorectal cancer prognosis incorporating perioperative longitudinal serum tumor markers: a retrospective longitudinal cohort study.
Li C; Zhao K; Zhang D; Pang X; Pu H; Lei M; Fan B; Lv J; You D; Li Z; Zhang T
BMC Med; 2023 Feb; 21(1):63. PubMed ID: 36803500
[TBL] [Abstract][Full Text] [Related]
7. Value of TCT combined with serum CA153 and CA50 in early diagnosis of cervical cancer and precancerous lesions.
Li H; Li L; Sun J; Dong S; Li H
Pak J Med Sci; 2022; 38(6):1471-1476. PubMed ID: 35991263
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Early Carcinoembryonic Antigen Change in Patients With Nonmetastatic Colorectal Cancer.
Jo Y; Lee JH; Cho ES; Lee HS; Shin SJ; Park EJ; Baik SH; Lee KY; Kang J
Front Oncol; 2022; 12():739614. PubMed ID: 35615159
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and Prognostic Values of Serum EpCAM, TGM2, and HE4 Levels in Endometrial Cancer.
Lan T; Mu C; Wang Z; Wang Y; Li Y; Mai Y; Li S; Xu H; Gu B; Luo L; Ma P
Front Oncol; 2020; 10():1697. PubMed ID: 33014844
[No Abstract] [Full Text] [Related]
10. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
11. XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
Guo Y; Xiong BH; Zhang T; Cheng Y; Ma L
Cancer Invest; 2016; 34(2):94-104. PubMed ID: 26864862
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy.
Mao J; Du P; Yang HT; Hu H; Wang SY; Wu X; Cheng ZB
Medicine (Baltimore); 2020 Apr; 99(14):e19420. PubMed ID: 32243362
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.
Buchler T; Pavlik T; Melichar B; Bortlicek Z; Usiakova Z; Dusek L; Kiss I; Kohoutek M; Benesova V; Vyzula R; Abrahamova J; Obermannova R
BMC Cancer; 2014 May; 14():323. PubMed ID: 24884897
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
